A contact lens for continuously enriching endogenous hyaluronic acid in the ocular surface and a method for preparing the same
By employing specific recognition and dynamic equilibrium mechanisms, combined with hyaluronic acid-binding peptides and methyl methacrylate to regulate the hydrogel network, the continuous enrichment of endogenous hyaluronic acid in contact lenses was achieved. This solved the problem of tear film homeostasis imbalance during long-term wear, improved lens wettability and mechanical stability, and reduced the risk of protein deposition and lipid contamination.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GANSU TIANHOU OPTICAL TECH CO LTD
- Filing Date
- 2026-04-22
- Publication Date
- 2026-06-05
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of contact lens technology, and more particularly to a contact lens that continuously enriches endogenous hyaluronic acid on the ocular surface and its preparation method. Background Technology
[0002] With the ever-expanding population of contact lens wearers, wearing comfort and ocular surface safety have become core focuses of industry research and development. The number of contact lens wearers continues to rise, but prolonged contact lens wear can easily trigger or exacerbate tear film homeostasis imbalance, leading to contact lens-related dry eye, manifested as discomfort such as dry eyes, foreign body sensation, and burning sensation. This is also one of the main reasons for the interruption or discontinuation of contact lens wear. Tear film stability is a prerequisite for safe and effective contact lens wear. Hyaluronic acid, as an important component of the ocular surface tear film, possesses excellent moisturizing, lubricating, adhesive, and biocompatibility properties. It can prolong tear film residence time, reduce tear evaporation, improve ocular surface lubrication, and reduce ocular surface protein adsorption, thus alleviating mechanical friction between the contact lens and the ocular surface. It is crucial for maintaining ocular surface health and is therefore widely used in artificial tears, eye care products, and contact lens modification to improve wearing comfort and ocular surface compatibility.
[0003] Currently, existing technologies for improving the moisturizing and lubricating performance of contact lenses mainly fall into two categories: one is to directly add exogenous hyaluronic acid to the contact lens material, utilizing its own moisturizing properties to improve the lens's hydration; the other is to introduce hydrophilic groups onto the lens surface through surface modification technology, enhancing the compatibility between the lens and tears. However, both methods have significant technical drawbacks: lenses with directly added exogenous hyaluronic acid are prone to losing hyaluronic acid on their surface due to tear rinsing and lens friction during wear, failing to achieve long-term moisturization and requiring frequent use of artificial tears. This not only increases the wearer's workload but may also disrupt the ocular surface microenvironment due to frequent use of artificial tears. On the other hand, surface hydrophilic modification technology often employs methods such as plasma treatment and wetting agent coating, resulting in weak bonding between the modified layer and the lens matrix. This leads to wear and failure after long-term wear, and it only improves the hydrophilicity of the lens surface, failing to actively utilize the ocular surface's own endogenous hyaluronic acid. The moisturizing and lubricating effect is limited and unsustainable, failing to fundamentally solve the problem of contact lens-related dry eye.
[0004] Furthermore, the composition and design of existing contact lens materials primarily focus on improving oxygen permeability and optical performance. For example, while silicone hydrogel materials significantly improve oxygen permeability and address corneal hypoxia, they still fall short in terms of sustained moisturizing and ocular surface compatibility. Their hydrophobic groups easily migrate to the lens-tear film interface, leading to gradual lens dryness and decreased lubrication, which can cause discomfort with prolonged wear. Simultaneously, current technologies lack contact lens designs that can actively and continuously enrich endogenous hyaluronic acid on the ocular surface. This prevents the full utilization of the body's own tears for long-lasting moisturizing and makes it difficult to simultaneously improve lens mechanical strength, biocompatibility, and moisturizing performance, thus failing to meet wearers' needs for long-term comfortable wear. Summary of the Invention
[0005] The purpose of this invention is to provide a contact lens that continuously enriches endogenous hyaluronic acid on the ocular surface and a method for preparing the same, in order to solve the above-mentioned technical problems.
[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a contact lens that continuously enriches endogenous hyaluronic acid on the ocular surface, prepared from raw materials comprising the following mass fractions: 70-90 wt% methacrylamide hyaluronic acid, 5-15 wt% methyl methacrylate, 2-8 wt% methacrylic acid, 0.05-0.5 wt% hyaluronic acid-binding peptide, and 0.05-1 wt% photoinitiator.
[0007] Furthermore, the molecular weight of the methacrylamide hyaluronic acid is 10~50 kDa.
[0008] This invention also provides a method for preparing contact lenses that continuously enrich endogenous hyaluronic acid from the ocular surface, comprising the following steps: Step 1) Dissolve hyaluronic acid-binding peptide and some methacrylamide hyaluronic acid in PBS buffer, and incubate to obtain peptide-HA nanocomplex. Step 2) Mix methyl methacrylate, methacrylic acid, the remaining methacrylamide hyaluronic acid and water, then add the photoinitiator until completely dissolved to obtain a premixed solution; Step 3) Mix the peptide-HA nanocomposite with the premixed liquid, degas it by ultrasound to obtain the molding liquid, then inject the molding liquid into the mold, let it stand, and then sequentially undergo photopolymerization, demolding and post-extraction to obtain the finished product.
[0009] Furthermore, in step 1), the mass ratio of the hyaluronic acid-binding peptide to methacrylamide hyaluronic acid is 1:5~10; The incubation is carried out under stirring at a speed of 100-150 rpm, at a temperature of 22-35°C, and for a time of 30-40 minutes.
[0010] Furthermore, in step 2), the mixing is carried out under stirring conditions, and the stirring speed is 300~500 rpm.
[0011] Furthermore, in step 3), the mixing is carried out under stirring conditions, with a stirring speed of 200~250 rpm and a stirring time of 5~10 min; The ultrasonic degassing process uses an ultrasonic frequency of 40-60 kHz and a duration of 5-8 minutes.
[0012] Furthermore, in step 3), the light intensity for photopolymerization is 10~20 mW / cm². 2 The time is 5-10 minutes.
[0013] Furthermore, in step 3), the post-extraction involves immersing the lens in PBS buffer for 20-30 hours.
[0014] The beneficial effects of this invention are: This invention achieves long-term and stable enrichment of endogenous HA. Hyaluronic acid-binding peptide (HABpep) serves as the core functional unit, specifically recognizing continuously secreted endogenous HA in tears. Simultaneously, methacrylic acid (MA) forms hydrogen bonds and electrostatic interactions with HA through its carboxyl group, creating a synergistic capture effect with HABpep, resulting in a lens HA binding capacity as high as 2.55~2.62 μg / cm³. 2 Unlike the physical adsorption mode of commercially available HA-coated lenses, this invention uses a "specific binding + dynamic balance" mechanism, achieving an HA retention rate of over 80% after 8 hours of wear and a retention rate of >95% in a 30-day cycle experiment, thus solving the problem of easy loss of exogenous HA.
[0015] This invention significantly improves the stain resistance and wettability of lenses. The enriched HA hydration layer reduces the lens contact angle to as low as 25°, while the lysozyme adsorption capacity is controlled at 3.9~4.3 μg / cm³. 2 The lipid adsorption capacity was controlled at 1.8~2.1 μg / cm³. 2 All were significantly lower than the control ratio, effectively reducing the risk of protein deposition, lipid pollution, and eye irritation caused by long-term wear.
[0016] This invention optimizes the overall performance and clinical applicability of contact lenses. The microscopic hydrophobic regions introduced by methyl methacrylate regulate the hydrogel network structure, ensuring light transmittance and oxygen permeability while avoiding excessive swelling, thus improving lens mechanical stability and wearing comfort. Compared to traditional products, this invention does not rely on exogenous HA eye drops, reducing the frequency of medication use and the risk of dry eye complications, providing a safer and longer-lasting moisturizing solution for long-term contact lens wearers. Detailed Implementation
[0017] This invention provides a contact lens that continuously enriches endogenous hyaluronic acid on the ocular surface, prepared from raw materials comprising the following mass fractions: 70-90 wt% methacrylamide hyaluronic acid, 5-15 wt% methyl methacrylate, 2-8 wt% methacrylic acid, 0.05-0.5 wt% hyaluronic acid-binding peptide, and 0.05-1 wt% photoinitiator.
[0018] In this invention, the amount of methacrylamide hyaluronic acid added is 75-85 wt% by mass fraction, more preferably 80 wt%.
[0019] In this invention, the amount of methyl methacrylate added is preferably 7-12 wt%, more preferably 10 wt%, by mass fraction.
[0020] In this invention, the amount of methacrylic acid added is preferably 5 wt% by mass fraction.
[0021] In this invention, the amount of hyaluronic acid-binding peptide added is preferably 0.1 to 0.3 wt% by mass fraction.
[0022] In this invention, the amount of photoinitiator added is preferably 0.1 to 0.8 wt%, more preferably 0.5 wt%, by mass fraction.
[0023] In this invention, the molecular weight of the methacryloyl hyaluronic acid is 10-50 kDa, preferably 20-40 kDa.
[0024] In this invention, the degree of substitution of the methacrylamide hyaluronic acid is preferably 30-50%.
[0025] In this invention, the photoinitiator includes lithium phenyl (2,4,6-trimethylbenzoyl) phosphate, i.e., LAP.
[0026] In this invention, the contact lens does not rely on exogenous HA eye drops. Instead, it enriches the endogenous HA continuously secreted in the tear film to form a dynamically renewed HA hydration layer on the lens surface, thereby reducing the patient's dependence on artificial tears.
[0027] In this invention, the hyaluronic acid-binding peptide (HABpep) is a known hyaluronic acid-binding peptide derived from phage display screening. It specifically binds to hyaluronic acid and is a conventionally known functional peptide in the art.
[0028] This invention also provides a method for preparing contact lenses that continuously enrich endogenous hyaluronic acid from the ocular surface, comprising the following steps: Step 1) Dissolve hyaluronic acid-binding peptide and some methacrylamide hyaluronic acid in PBS buffer, and incubate to obtain peptide-HA nanocomplex. Step 2) Mix methyl methacrylate, methacrylic acid, the remaining methacrylamide hyaluronic acid and water, then add the photoinitiator until completely dissolved to obtain a premixed solution; Step 3) Mix the peptide-HA nanocomposite with the premixed liquid, degas it by ultrasound to obtain the molding liquid, then inject the molding liquid into the mold, let it stand, and then sequentially undergo photopolymerization, demolding and post-extraction to obtain the finished product.
[0029] In this invention, in step 1), the mass ratio of the hyaluronic acid binding peptide to methacrylamide hyaluronic acid is 1:5~10, preferably 1:7; The incubation is carried out under stirring, with a stirring speed of 100~150 rpm, preferably 120 rpm; the incubation temperature is 22~35℃, preferably 27~32℃; and the incubation time is 30~40 min, preferably 35 min.
[0030] In this invention, hyaluronic acid binding peptide (HABpep) is used to bind endogenous HA in tears, while the carboxyl group of methacrylic acid has a non-specific affinity for HA through hydrogen bonding and electrostatic interaction, which can form a synergistic capture effect with HABpep.
[0031] In this invention, hyaluronic acid-binding peptides and low molecular weight methacrylamide hyaluronic acid are pre-bound to protect the activity of HABpep and prevent it from being embedded too deeply or becoming unstable or even inactive during subsequent polymerization.
[0032] In this invention, the hydrophobic segments introduced by methyl methacrylate form micro-hydrophobic regions in the hydrogel network, regulating the network pore size and swelling behavior, thereby controlling the exposure mechanism of the peptide-HA nanocomposite and achieving continuous enrichment rather than one-time release.
[0033] In this invention, in step 2), the mixing is carried out under stirring conditions, and the stirring speed is 300~500 rpm, preferably 350~450 rpm, and more preferably 400 rpm.
[0034] In this invention, in step 2), the pH of the mixture obtained by mixing methyl methacrylate, methacrylic acid, the remaining methacrylated hyaluronic acid and water is 7.0~7.2, and the pH adjuster for adjusting the system is 0.1M NaOH solution or 0.1M HCl solution.
[0035] In this invention, in step 3), the mixing is carried out under stirring conditions, the stirring speed is 200~250 rpm, preferably 220 rpm; the stirring time is 5~10 min, preferably 8 min; The ultrasonic degassing process uses an ultrasonic frequency of 40-60 kHz, preferably 50 kHz, and a duration of 5-8 min, preferably 7 min.
[0036] In this invention, in step 3), the light intensity for photopolymerization is 10~20 mW / cm². 2 The preferred value is 12~18mW / cm 2 The time is 5-10 minutes, preferably 8 minutes.
[0037] In this invention, in step 3), the post-extraction involves immersing the lens in PBS buffer for 20-30 hours, preferably 22-28 hours, and more preferably 25 hours.
[0038] In this invention, the pH of the PBS buffer is 7.2-7.4 and the concentration is 10mM.
[0039] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.
[0040] Example 1
[0041] 0.01 g of hyaluronic acid-binding peptide and 0.1 g of methacrylamide hyaluronic acid were sequentially dissolved in 5 mL of 10 mM PBS buffer. The mixture was then placed on a magnetic stirrer and incubated in the dark at 100 rpm and 27 °C for 30 min to obtain the peptide-HA nanocomplex solution. Take 7.4g of methacrylamide hyaluronic acid, 0.7g of methyl methacrylate, 0.5g of methacrylic acid and 15g of deionized water and mix them. Stir for 30min at 350rpm and 27℃. Adjust the pH of the system to 7.0, add 0.01g of photoinitiator LAP, and continue stirring for 15min to obtain the premixed solution. The peptide-HA nanocomposite solution was slowly added to the premixed solution and gently stirred for 5 min at 200 rpm and 25 °C. Then, it was ultrasonically degassed for 8 min at 40 kHz and 120 W to obtain the molding solution. Slowly inject the molding liquid into the polypropylene mold, let it stand at room temperature for 5 minutes, and then expose it to light at a wavelength of 365 nm and an intensity of 12 mW / cm². 2Under nitrogen atmosphere protection, the polymer was photopolymerized for 10 min. After demolding, the lenses were immersed in 50 mL of PBS buffer and soaked at 4 °C for 22 h before extraction. The buffer was changed three times during this period to remove unreacted monomers and residues. The resulting lenses were then dried, sealed, and sterilized sequentially to obtain contact lenses that continuously enrich endogenous hyaluronic acid from the ocular surface.
[0042] Example 2
[0043] 0.02 g of hyaluronic acid-binding peptide and 0.14 g of methacrylamide hyaluronic acid were sequentially dissolved in 5 mL of 10 mM PBS buffer. The mixture was then placed on a magnetic stirrer and incubated in the dark at 120 rpm and 30 °C for 35 min to obtain the peptide-HA nanocomposite solution. Take 7.8g of methacrylamide hyaluronic acid, 1.0g of methyl methacrylate, 0.5g of methacrylic acid and 15g of deionized water and mix them. Stir for 30min at 400rpm and 28℃. Adjust the pH of the system to 7.0, add 0.05g of photoinitiator LAP, and continue stirring for 15min to obtain the premixed solution. The peptide-HA nanocomposite solution was slowly added to the premixed solution and gently stirred for 8 minutes at a speed of 220 rpm and a temperature of 25°C. Then, it was ultrasonically degassed for 8 minutes at a frequency of 50 kHz and a power of 120 W to obtain the molding solution. Slowly inject the molding liquid into the polypropylene mold, let it stand at room temperature for 5 minutes, and then expose it to light at a wavelength of 365 nm and an intensity of 18 mW / cm². 2 Under nitrogen atmosphere protection, the polymer was photopolymerized for 8 minutes. After demolding, the lenses were immersed in 50 mL of PBS buffer and soaked at 4°C for 22 hours before extraction. The buffer was changed three times during this period to remove unreacted monomers and residues. The resulting lenses were then dried, sealed, and sterilized sequentially to obtain contact lenses that continuously enrich endogenous hyaluronic acid from the ocular surface.
[0044] Example 3
[0045] 0.03 g of hyaluronic acid-binding peptide and 0.21 g of methacrylamide hyaluronic acid were sequentially dissolved in 5 mL of 10 mM PBS buffer. The mixture was then placed on a magnetic stirrer and incubated in the dark at 150 rpm and 27 °C for 40 min to obtain the peptide-HA nanocomposite solution. Take 7.7g of methacrylamide hyaluronic acid, 1.2g of methyl methacrylate, 0.5g of methacrylic acid and 15g of deionized water and mix them. Stir for 30min at 450rpm and 27℃. Adjust the pH of the system to 7.2, add 0.08g of photoinitiator LAP, and continue stirring for 15min to obtain the premixed solution. The peptide-HA nanocomposite solution was slowly added to the premixed solution and gently stirred for 10 min at a speed of 250 rpm and a temperature of 25 °C. Then, it was ultrasonically degassed for 5 min at a frequency of 60 kHz and a power of 120 W to obtain the molding solution. Slowly inject the molding liquid into the polypropylene mold, let it stand at room temperature for 5 minutes, and then expose it to light at a wavelength of 365 nm and an intensity of 18 mW / cm². 2 Under nitrogen atmosphere protection, the polymer was photopolymerized for 5 minutes. After demolding, the lenses were immersed in 50 mL of PBS buffer and soaked at 4°C for 24 hours before extraction. The buffer was changed three times during this period to remove unreacted monomers and residues. The resulting lenses were then dried, sealed, and sterilized sequentially to obtain contact lenses that continuously enrich endogenous hyaluronic acid from the ocular surface.
[0046] Comparative Example 1
[0047] Unlike Example 1, the addition of hyaluronic acid-binding peptides was omitted in this comparative example.
[0048] Comparative Example 2
[0049] Unlike Example 1, the addition of methyl methacrylate and methacrylic acid was omitted in this comparative example.
[0050] Comparative Example 3
[0051] The base lens was rinsed with 10 mM PBS buffer to remove the surface preservation solution. Then the lens was completely immersed in 0.1 wt% HA solution and incubated at room temperature for 24 h. After that, the lens was sterilized in 2 mL of PBS buffer to obtain the HA coated lens.
[0052] 1) Performance Testing
[0053] The products obtained in Examples 1-3 and Comparative Examples 1-3 were subjected to performance tests. The test items and test methods are as follows: Transmittance: UV-Vis spectrophotometry, wavelength 380~780nm, ISO 18369-3; Moisture content: Gravimetric method (dry weight / wet weight difference), ISO 18369-4; HA binding capacity: ELISA method, the lens was immersed in artificial tears containing physiological concentration of HA for 24 hours and then measured; Lysozyme adsorption: HPLC-electrochemical detection method, followed by determination of tryptophan residues after hydrolysis; Contact angle: ISO 18369-4; Oxygen permeability coefficient: ISO 18369-4; Lipid adsorption: Cholesterol was extracted with chloroform-methanol, quantified by thin-layer chromatography, and detected by thin-layer chromatography. Mechanical properties: ISO 18369-3; Cytotoxicity assay: MTT assay was used. L929 fibroblasts were cultured in lens extract (37℃, 24h) for 72h, and then cell viability was detected. End-of-cycle performance: 30-day cycle experiment: 8 hours of artificial tear incubation + 16 hours of preservation solution immersion daily, with periodic measurement of HA binding and protein adsorption.
[0054] Table 1. Performance characteristics of the contact lenses obtained in Examples 1-3 and Comparative Examples 1-3
[0055] Table 1 shows that Example 2 performed best in terms of stain resistance, moisture retention, and wettability, while Example 1 performed best in terms of light transmittance and oxygen permeability. Comparative Example 1, without the addition of HABpep, showed low HA binding, indicating that HABpep is the core component for HA capture. The highest adsorption of lysozyme indicates severe protein deposition.
[0056] Table 2. HA retention rate (μg / cm³) of the contact lenses obtained in Example 2 and Comparative Example 3 under dynamic tear flushing. 2 )
[0057] As shown in Table 2, in Example 2, the HA retention rate is high due to the specific binding of HABpep; in Comparative Example 3, the physically adsorbed HA is rapidly lost under scouring.
[0058] Table 3. End-cycle performance characterization and swelling rate of contact lenses obtained in Example 1 and Comparative Examples 2 and 3
[0059] As shown in Table 3, the HA binding amount in Example 1 remained stable over the 30-day period, demonstrating its ability to continuously capture endogenous HA. In Comparative Example 2, without the addition of methyl methacrylate and methacrylic acid, the HA binding amount decreased significantly, proving that methyl methacrylate and methacrylic acid have stabilizing effects. In Comparative Example 3, the HA coating was physically bound to the substrate lens, and by day 30, the HA was almost completely lost, while protein adsorption increased significantly, proving that simple physical adsorption is not effective for long-term results. In addition, after 30 days, the swelling rate of the lens in Example 1 was still <10%, proving that the network regulation function of MMA was not excessively expanded due to the continuous binding of HA, and it has long-term stability.
[0060] 2) Biosafety verification
[0061] The ocular surface safety of the samples was evaluated using a rabbit eye irritation test, designed according to ISO 9394:2012. The contact lenses prepared in Example 2 were used as the test samples, and commercially available soft contact lenses without hyaluronic acid coating served as negative controls. Healthy New Zealand white rabbits, weighing 2.0–3.0 kg, with an equal number of males and females, were selected as the test animals. The animals were physically healthy, with no eye diseases, discharge, or conjunctival congestion in either eye. The rabbits underwent at least 5 days of quarantine and environmental acclimatization before the experiment, and both eyes were examined 24 hours prior to the experiment to confirm the absence of abnormalities in the cornea, conjunctiva, and iris before inclusion in the formal experiment.
[0062] Wearing and Observation Procedure: On day 0 before the experiment, a comprehensive examination of both eyes was performed using a slit-lamp microscope, and baseline scores of the cornea, conjunctiva, iris, and other tissues were recorded. Lens wearing was completed on day 0, with the test lens gently placed in the center of the rabbit's cornea, ensuring good adhesion and stable position; the blank control group animals did not wear lenses. From the date of wearing, the lens's position and detachment status were observed daily on days 1, 2, 3, 7, 14, and 21, and the tissue reactions of the conjunctiva, cornea, and iris were examined using a slit-lamp microscope. On day 7, the lens was briefly removed to examine the corneal condition. If significant contamination or protein deposition was observed, the lens was replaced according to relevant standards. The experiment terminated on day 21. After removing the lens, a comprehensive examination was performed again using a slit-lamp microscope, and corneal tissue was taken for histopathological examination.
[0063] Observation indicators: The observation indicators include the degree of corneal opacity (including opacity density and affected area), iris congestion and edema and abnormal reactions, conjunctival congestion, conjunctival edema and conjunctival secretions.
[0064] Scoring criteria: Corneal opacity: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe; Iris reaction: 0 = normal; 1 = significant congestion / swelling; 2 = severe reaction; Conjunctival congestion / edema / discharge: 0-3 points each (0=none, 1=mild, 2=moderate, 3=severe); The results showed that mild conjunctival hyperemia occurred in the experimental group on day 1, which was a normal mechanical stimulation response in the early stages of wear and completely subsided on day 3. No abnormalities were found at other time points or in any group. Histopathological examination showed that the corneal epithelium in the experimental group was intact, with no stromal edema or inflammatory cell infiltration, and there was no significant difference compared with the negative control group and the blank control group. The average total score of the experimental group on day 21 was <0.2, far below the threshold of 5, consistent with the performance of the negative control group, and was judged to be non-irritating, meeting the requirements for biocompatibility.
[0065] As can be seen from the above embodiments, the present invention provides a contact lens that continuously enriches endogenous hyaluronic acid from the ocular surface and its preparation method. Hyaluronic acid-binding peptides are the core functional units for capturing endogenous HA. Methacrylic acid forms hydrogen bonds with HA through its carboxyl group, forming a synergistic capture effect with HABpep through specific recognition and non-specific affinity. The micro-hydrophobic regions introduced by methyl methacrylate regulate the pore size and swelling behavior of the hydrogel network, achieving stable exposure and long-term release of the peptide-HA complex.
[0066] Unlike the physical adsorption mode of traditional commercially available HA-coated lenses, the lens of this invention enriches the endogenous HA continuously secreted in tears through a mechanism that combines specific binding with dynamic equilibrium. After 8 hours of wear, it still retains more than 80% of the HA binding amount, and in a 30-day cycle experiment, the HA binding amount retention rate is >95%, avoiding the problem of rapid loss of exogenous HA.
[0067] The enriched HA hydration layer not only improves lens wettability but also significantly reduces lysozyme and lipid adsorption, solving the problem of protein and lipid deposition in traditional contact lenses with long-term wear. The contact lens provided by this invention, which continuously enriches endogenous hyaluronic acid on the ocular surface, overcomes the technical limitations of traditional moisturizing contact lenses through the synergistic design of functional components and a dynamic enrichment mechanism, possessing significant technical advantages and application value.
[0068] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A contact lens that continuously enriches endogenous hyaluronic acid on the ocular surface, characterized in that, It is prepared from raw materials comprising the following mass fractions: 70-90 wt% methacrylamide hyaluronic acid, 5-15 wt% methyl methacrylate, 2-8 wt% methacrylic acid, 0.05-0.5 wt% hyaluronic acid-binding peptide, and 0.05-1 wt% photoinitiator.
2. The contact lens that continuously enriches endogenous hyaluronic acid on the ocular surface according to claim 1, characterized in that, The molecular weight of the methacryloyl hyaluronic acid is 10~50kDa.
3. The method for preparing contact lenses with continuous enrichment of endogenous hyaluronic acid from the ocular surface as described in claim 1 or 2, characterized in that, Includes the following steps: Step 1) Dissolve hyaluronic acid-binding peptide and some methacrylamide hyaluronic acid in PBS buffer, and incubate to obtain peptide-HA nanocomplex. Step 2) Mix methyl methacrylate, methacrylic acid, the remaining methacrylamide hyaluronic acid and water, then add the photoinitiator until completely dissolved to obtain a premixed solution; Step 3) Mix the peptide-HA nanocomposite with the premixed liquid, degas it by ultrasound to obtain the molding liquid, then inject the molding liquid into the mold, let it stand, and then sequentially undergo photopolymerization, demolding and post-extraction to obtain the finished product.
4. The method for preparing contact lenses with continuous enrichment of endogenous hyaluronic acid from the ocular surface according to claim 3, characterized in that, In step 1), the mass ratio of the hyaluronic acid-binding peptide to methacrylamide hyaluronic acid is 1:5~10; The incubation is carried out under stirring at a speed of 100-150 rpm, at a temperature of 22-35°C, and for a time of 30-40 minutes.
5. The method for preparing contact lenses with continuous enrichment of endogenous hyaluronic acid from the ocular surface according to claim 3 or 4, characterized in that, In step 2), the mixing is carried out under stirring conditions, and the stirring speed is 300~500 rpm.
6. The method for preparing contact lenses with continuous enrichment of endogenous hyaluronic acid from the ocular surface according to claim 5, characterized in that, In step 3), the mixing is carried out under stirring conditions, with a stirring speed of 200~250 rpm and a stirring time of 5~10 min; The ultrasonic degassing process uses an ultrasonic frequency of 40-60 kHz and a duration of 5-8 minutes.
7. The method for preparing contact lenses with continuous enrichment of endogenous hyaluronic acid from the ocular surface according to claim 6, characterized in that, In step 3), the light intensity for photopolymerization is 10~20 mW / cm². 2 The time is 5-10 minutes.
8. The method for preparing contact lenses with continuous enrichment of endogenous hyaluronic acid from the ocular surface according to claim 6, characterized in that, In step 3), the post-extraction involves immersing the lens in PBS buffer for 20-30 hours.